Thyrotropin-releasing Hormone Can Relieve Cancer-related Fatigue: Hypothesis and Preliminary Observations  

Oleh:

Kamath, J. ; Yarbrough, G.G. ; Prange, A.J., (Jr.) ; Winokur, A.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 37 no. 04 (Jul. 2009), page 1152-1157.
Topik: Thyrotropin-releasing hormone; cancer-related fatigue; breast cancer; homeostasis

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K.2009.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Fatigue in cancer patients is highly prevalent, predominantly idiopathic, difficult to manage, and has a significant negative impact on quality of life. Thyrotropin-releasing hormone (TRH) exerts normotrophic, state-dependent therapeutic effects in a variety of experimental and clinical situations. To evaluate TRH as a treatment for cancer-related fatigue, an ongoing randomized, placebo-controlled, crossover pilot study of breast cancer patients has been initiated and this report presents preliminary observations conducted with three of these patients over 4 consecutive weeks, thereby involving a total of six TRH treatments and six saline controls. Global assessment using both subjective and objective parameters showed that TRH exerted clear anti-fatigue effects in four of the six TRH treatments. These responses were rapid in onset and persisted through the 24 h observation period. No anti-fatigue responses were seen in five of the six saline controls. No unexpected side-effects were seen with TRH administration. These initial findings support the proposal that TRH can ameliorate cancer-related fatigue.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali